98
Views
4
CrossRef citations to date
0
Altmetric
Special Report

Challenges in funding diabetes care: a health economic perspective

Pages 517-524 | Published online: 09 Jan 2014

References

  • IDF Diabetes Atlas. International Diabetes Federation (4th Edition). International Diabetes Federation, Brussels, Belgium (2009).
  • American diabetes association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31(3), 1–20 (2008).
  • Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol. Ther.10(Suppl. 1), S72–S81 (2008).
  • International Bank for Reconstruction and Development, The World Bank. (2005) International Comparision Program. Preliminary Results. The World Bank, Washington DC, USA (2007).
  • Zhang PP, Engelgau MMM, Norris SLM et al. Application of economic analysis to diabetes and diabetes care. Ann. Intern. Med.140(11), 972–977 (2004).
  • Cefalu W. Economics of diabetes – cost impact of not treating diabetes early and intensively. Clin. Cornerstone6(2), 51–58 (2004).
  • Goldfarb N, Weston C, Hartmann CW et al. Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. Dis. Manag.7(1), 61–75 (2004).
  • Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344(18), 1343–1350 (2001).
  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358(6), 580–591 (2008).
  • Ribisl PM, Lang W, Jaramillo SA et al. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with Type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care30(10), 2679–2684 (2007).
  • Loveman E, Frampton GK, Clegg AJ. The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review. Health Technol. Assess.12(9), 1–116 (2008).
  • Christensen NK, Williams P, Pfister R. Cost Savings and clinical effectiveness of an extension service diabetes program. Diabetes Spectr.17(3), 171–175 (2004).
  • Mortimer D, Kelly J. Economic evaluation of the good life club intervention for diabetes self-management. Aus. J. Primary Health12(1), 91–100 (2006).
  • IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Federation, Brussels, Belgium (2005).
  • American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care32(Suppl. 1), S13–S61 (2009).
  • National Collaborating Centre For Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians, London, UK (2009).
  • Colagiuri S, Dickinson S, Girgis S, Colagiuri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the NHMRC. Canberra, ACT, Australia (2009).
  • Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics15(6), 583–595 (1999).
  • Brouwer WB, Koopmanschap MA. How to calculate indirect costs in economic evaluations. Pharmacoeconomics13(5 Pt 1), 563–569 (1998).
  • DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. the Diabetes Control and Complications Trial research group. N. Engl. J. Med.329(14), 977–986 (1993).
  • Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet352(9131), 837–853 (1998).
  • Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35), prospective observational study. BMJ321(7258), 405–412 (2000).
  • Singer DE, Coley CM, Samet JH, Nathan DM. Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. Ann. Intern. Med.110(2), 125–137 (1989).
  • Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N. Engl. J. Med.310(6), 341–346 (1984).
  • Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care18(4), 440–447 (1995).
  • Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol. Ther.11(10), 623–633 (2009).
  • Weinstein MC, Toy EL, Sandberg EA et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health4(5), 348–361 (2001).
  • American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care27(9), 2262–2265 (2004).
  • Weinstein MC. A Report of the ISPOR Health Science Committee – Task Force on Good Research Practices – Modeling Studies. (2005).
  • Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care30(6), 1638–1646 (2007).
  • Broome J. Trying to value a life. J. Pub. Econ.9, 91–100 (1982).
  • Karlsson G, Johannesson M. The decision rules of cost–effectiveness analysis. Pharmacoeconomics9(2), 113–120 (1996).
  • Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ.16(1), 1 (1997).
  • Olsen JA. Theories of justice and their implications for priority setting in health care. J. Health Econ.16(6), 625–639 (1997).
  • Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J. Pub. Econ.2, 147–157 (1973).
  • Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics24(11), 1121–1131 (2006).
  • Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost–effectiveness threshold. J. Health Serv. Res. Policy11(1), 46–51 (2006).
  • Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics19(6), 609–621 (2001).
  • Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics20(12), 855–867 (2002).
  • Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health7(1), 1–10 (2004).
  • Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev. Pharmacoeconomics Outcomes Res.5(1), 65–79 (2005).
  • Sendi PP, Briggs AH. Affordability and cost–effectiveness: decision-making on the cost–effectiveness plane. Health Econ.10(7), 675–680 (2001).
  • Hirth RA, Chernew ME, Miller E et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20(3), 332–342 (2000).
  • Kaplan R, Bush J. Health related quality of life measurement for evaluation research and policy analysis. Health Psychol.1, 61–80 (1982).
  • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ146(4), 473–481 (1992).
  • Stevens A, Colin-Jones D, Gabbay J. ‘Quick and clean’: authoritative health technology assessment for local health care contracting. Health Trends27(2), 37–42 (1995).
  • Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ.13(5), 437–452 (2004).
  • George B, Harris A, Mitchell A. Cost–effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics19(11), 1103–1109 (2001).
  • Council for Public Health and Health Care. Sensible and Sustainable Care. Recommendations by the Council for Public Health and Health Care to the Minister of Health, Wefare and Sports (2006).
  • Dardis R. The value of life: new evidence from the marketplace. Am. Econ. Rev.70(5), 1077–1082 (1980).
  • Ippolito P, Ippolito R. Measuring the value of live saving from consumer reactions to new information. J. Pub. Econ.25, 53–81 (1984).
  • Lanoie P, Pedro C, Latour R. The value of a statistical life: a comparision of two approaches. J. Risk Uncertain.10, 235–257 (1995).
  • Miller T. Variations between countries in values of statistical life. J. Transport Econ. Pol.34(2), 169–188 (2000).
  • Mrozek J, Taylor L. What determines the value of life? A meta-analysis. J. Pol. Anal. Manage.21(2), 253–270 (2002).
  • Tengs T, Adams M, Pliskin J et al. Five-hundred life-saving interventions and their cost–effectiveness. Risk Anal.15(3), 369–390 (1995).
  • Viscusi W, Aldy J. The Value of a Statistical Life: a Critical Review of Market Estimates Throughout the World. NBER Working Paper 9487, MA, USA (2003).
  • The World Bank. World Development Report. The World Bank, Washington, DC, USA (1993).
  • Anand S, Hanson K. Disability-adjusted life years: a critical review. J. Health Econ.16(6), 685–702 (1997).
  • Arnesen T, Nord E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ319(7222), 1423–1425 (1999).
  • Drummond M, Torrance G, Mason J. Cost–effectiveness league tables: more harm than good? Soc. Sci. Med.37(1), 33–40 (1993).
  • Sach TH, Smith RD, Whynes DK. A ‘league table’ of contingent valuation results for pharmaceutical interventions: a hard pill to swallow? Pharmacoeconomics25(2), 107–127 (2007).
  • Luce BR, Mauskopf J, Sloan FA et al. The return on investment in health care: from 1980 to 2000. Value Health9(3), 146–156 (2006).
  • Mc Kee M, Nolte E, Suhrcke M. The Value of Health Improvements in the European Union. London School of Hygiene and Tropical Medicine, London, UK (2005).
  • Nordhaus W, Tobin J. Is Growth Obsolete? Columbia University Press, NY, USA (1972).
  • Daly HE, Cobb J. For the Common Good. Redirecting the Economy Toward Community, the Environment and a Sustainable Future. Beacon Press, MA, USA (1994).
  • Ul Haq M. Reflections on Human Development. Oxford University Press, NY, USA (1995).
  • King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med. Decis. Making25(6), 667–677 (2005).
  • Guria J, Leung J, Jones-Lee M, Loomes G. The willingness to accept value of statistical life relative to the willingness to pay value: evidence and policy implications. Environmental Res. Econ.32(1), 113–127 (2005).
  • Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy74(1), 77–84 (2005).
  • Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics23(5), 423–432 (2005).
  • Richardson J, Smith RD. Calculating society’s willingness to pay for a QALY: key questions for discussion . Appl. Health Econ. Health Policy3(3), 125–116 (2004).
  • Philipson T, Becker G, Goldman D, Murphy K. Terminal care and the value of life near its end. The Milton Friedman Institute For Research in Economics, Report No.: MFI Working Paper Series Chicago, IL, USA (2010).
  • Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ148(6), 913–917 (1993).
  • Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should ‘reasonable decisions’ lead to uncontrolled growth in expenditures? CMAJ168(7), 849–851 (2003).
  • Suhrcke M, Mc Kee M, Sauto-Arce R et al.The Contribution of Health to the Economy in the European Union. Office for Pfficial Publications of the European Communities Luxembourg (2005).
  • Nordhaus W. The health of nations: the contribution of improved health to living standards. In: The Measurement of Economic and Social Performance. Moss M (Eds). Columbia University Press for National Bureau of Economic Research, NY, USA (2003).
  • Shillcutt S, Walker D, Goodman C, Mills A. Cost effectiveness in low- and middle-income countries. A review of the debates surrounding decision rules. Pharmacoeceonomics27(11), 903–917 (2009).
  • Ham C. Retracing the Oregon trail: the experience of rationing and the Oregon health plan. BMJ316(7149), 1965–1969 (1998).
  • Blumstein JF. The Oregon experiment: the role of cost–benefit analysis in the allocation of Medicaid funds. Soc. Sci. Med.45(4), 545–554 (1997).
  • Dolan P, Metcalfe R, Munro V, Christensen M. Valuing lives and life years: anomalies, implications, and an alternative. Health Econ. Pol. Law3, 277–300 (2008).
  • Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost–effectiveness analysis. Health Policy Plan16(3), 326–331 (2001).
  • Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost–effectiveness from multinational clinical trials. Health Econ.7(6), 481–493 (1998).
  • Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat. Med.22(12), 1955–1976 (2003).
  • Pinto EM, Willan AR, O’Brien BJ. Cost–effectiveness analysis for multinational clinical trials. Stat. Med.24(13), 1965–1982 (2005).
  • Manca A, Willan A. Lost in translation: accounting for between-country differences in the analysis of multinational cost–effectiveness data. Pharmacoeconomics24(11), 1101–1119 (2006).
  • Willan AR, Pinto EM, O’Brien BJ et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ.14(4), 327–338 (2005).
  • Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost–effectiveness analysis: the use of multilevel models. Health Econ.14(5), 471–485 (2005).
  • Hopkins S, Varjonen S. Development of Health-Specific Purchasing Power Parities: General Principles and Problems in Measurement of Health Services Across Countries. OECD Report No.: DELSA/HEA/HA/PPP (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.